ESR1 and breast carcinoma: We developed an organotypic breast model based on the ER-driven breast cancer adverse outcome pathway, which helped frame which readouts (e.g. ER transactivation, apoptosis, proliferation and hyperplasia) and cellular components (e.g. fibroblasts) were most critical when modeling ER + breast cancer progression, a concept we have published previously10.